勃林格殷格翰将评估Dll3靶向T细胞衔接器联合PD-L1/VEGF-A双特异性抗体治疗小细胞肺癌

美股速递
Apr 09

勃林格殷格翰宣布将开展临床研究,评估其Dll3靶向T细胞衔接器与PD-L1/VEGF-A双特异性抗体联合疗法在小细胞肺癌治疗中的潜力。该联合方案旨在通过不同机制协同作用,为这种侵袭性肺癌患者探索新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10